Loyal Launches Clinical Study for LOY-002, Aiming to Extend Lifespan in Senior Dogs

Key Insights

• Loyal has initiated a clinical study named STAY to evaluate LOY-002, a drug designed to extend lifespan and enhance the quality of life for senior dogs.
• The STAY study plans to enroll 1,000 senior dogs across 70 veterinary clinics in the United States, encompassing dogs of nearly all sizes.
• LOY-002 represents a significant effort to address aging and improve healthspan in canines, potentially transforming veterinary care for older dogs.

Loyal, a company focused on extending the healthy lifespan of dogs, has announced the launch of a major clinical study, STAY, for its drug candidate LOY-002. The study aims to evaluate the efficacy of LOY-002 in extending lifespan and maintaining quality of life in senior dogs.

The STAY study is set to enroll 1,000 senior dogs of nearly all sizes across 70 veterinary clinics throughout the United States. This large-scale trial underscores Loyal's commitment to rigorous scientific evaluation of its therapies.

LOY-002 represents a novel approach to addressing aging in canines, with the goal of not only extending life but also improving the overall well-being of senior dogs. Further details about the mechanism of action and specific endpoints of the study were not disclosed in the announcement, but the company has indicated that participation details are available on their website.